Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Release Date: January 30, 2026

Expiration Date: January 30, 2027

Expiration Date: 

Activity Overview

An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. The intensive 3-day interactive program provides a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators.

This educational activity is an archive of the live program held from November 6 to 8, 2025.

Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who desire to increase their knowledge and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate molecular and genomic testing into the treatment planning process to select the optimal therapeutic strategies for individual patients with breast cancer
• Explore current and emerging imaging modalities, and their appropriate uses, for diagnosing, staging, and monitoring patients with breast cancer
• Discuss best practices and emerging approaches in the locoregional management of breast cancer, including surgical and radiation modalities, and the role of multidisciplinary treatment planning, to optimize patient outcomes and prevent or minimize adverse events
• Assess foundational evidence from clinical trials establishing current standards in systemic therapies for breast cancer, and emerging results from trials evaluating novel strategies that may shape future treatment options

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.